-
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies Posted on by TrueParallel in News&Uncategorized
-
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease Posted on by TrueParallel in News&Uncategorized
-
AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial Posted on by TrueParallel in News&Uncategorized
-
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024 Posted on by TrueParallel in News&Uncategorized
-
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure Posted on by TrueParallel in News&Uncategorized
-
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease Posted on by TrueParallel in News&Uncategorized
-
AskBio Names Mansuo Shannon Chief Scientific Officer Posted on by TrueParallel in News
-
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure Posted on by TrueParallel in News&Uncategorized
-
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint Posted on by TrueParallel in News&Uncategorized
-
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P) Posted on by TrueParallel in News&Uncategorized
